Efficacy,Tolerability,Safety of Temsirolimus in Women With Platinum-refractory Ovarian Carcinoma or Advanced Endometrial Carcinoma
The purpose of this study is to determine the activity, tolerability and safety of Temsirolimus in women with ovarian cancer who progressed during the previous platinum chemotherapy alternatively within 6 months from completion of therapy or advanced endometrial carcinoma.
Genital Diseases, Female|Ovarian Diseases|Ovarian Neoplasms|Endometrial Neoplasms
DRUG: Temsirolimus
progression-free survival, after 4 months for ovarian cancer and 6 months for endometrial carcinoma after study entry
rate and duration of stable diseases according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 and Gynecologic Cancer Intergroup (GCIG)-criteria for ovarian cancer, every 8 weeks until progression|progression-free survival according to RECIST 1.1 and cancer antigen 125 (CA 125) (for ovarian cancer) (biological progression-free survival (PFSbio)), every 8 weeks until progression|overall survival, weekly until progression; thereafter every 8 weeks|safety and toxicity, i.e. type, frequency, severity and duration of adverse reactions, weekly until progression; thereafter every 8 weeks|quality of life according to European Organisation for Research and Treatment of Cancer (EORTC) questionaires "QLQ C30", "QLQ OV28" and "QLQ-EN24", every 8 weeks|rate and duration of stable diseases according to RECIST-criteria for endometrial cancer, every 8 weeks until progression
The purpose of this study is to determine the activity, tolerability and safety of Temsirolimus in women with ovarian cancer who progressed during the previous platinum chemotherapy alternatively within 6 months from completion of therapy or advanced endometrial carcinoma.